MPN Hub
MPN Hub
✓

Symposium | Navigating therapeutic options for patients with cytopenic MF

00:13:35
Podcasts
RSS
Link

ABOUT THIS EPISODE

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigating therapeutic options for patients with cytopenic myelofibrosis. 


In this presentation, Koschmieder discusses current therapeutic approaches to cytopenic MF, including a review of key data on outcomes with momelotinib, pacritinib, luspatercept, and pelabresib and selinexor in combination with ruxolitinib.


This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence

Hosted on Acast. See acast.com/privacy for more information.

Education
English
United States
Use API to fetch this episode in JSON

IN THIS EPISODE

Edit these tags

TRANSCRIPT 🔗

Are you the producer of this podcast? Add a podcast transcript
Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

SEARCH PAST EPISODES

Search past episodes of MPN Hub.
Embed this search bar to your website

OTHER EPISODES IN THIS PODCAST

ASH 2025 | Nuvisertib + momelotinib in patients with R/R MF: Phase I/II findings

ASH 2025 | Nuvisertib + momelotinib in patients with R/R MF: Phase I/II findings

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of…
00:03:37
SHARE
SAVE
Symposium | Cytopenias in MF: Clinical burden and the need for prioritized management

Symposium | Cytopenias in MF: Clinical burden and the need for prioritized management

Hello, and welcome to our podcast. Today, Jean-Jacques Kiladjian, Consultant Hematologist from the Université Paris Cité - Hôpital Saint-Louis, Paris, France, discusses cytopenias in myelofibrosis, with a focus on clinical burden and the need for prioritized management.   This educational…
00:07:11
SHARE
SAVE
ASH 2025 | What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?

ASH 2025 | What are the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study?

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université Paris Cité, Paris, FR. We asked, What are the key findings from …
00:07:25
SHARE
SAVE
How might extended-release formulations of ruxolitinib benefit patients with MF?

How might extended-release formulations of ruxolitinib benefit patients with MF?

The MPN Hub was pleased to speak with Jennifer Vaughn, The Ohio State University Comprehensive Cancer Center, Columbus, US. We asked, How might extended-release formulations of ruxolitinib benefit patients with MF? In this interview, Vaughn discusses the potential benefits of an extended-release r…
00:03:23
SHARE
SAVE
Disclaimer: The podcast and artwork embedded on this page are from Scientific Education Support, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
PROMOTED
Listen411.com: Lightning-fast Podcast Transcription and Summarization. Transcribe 1-hour audio in under 1 minute. Pay-as-you-go.
Listen411.com: Lightning-fast Podcast Transcription and Summarization. Transcribe 1-hour audio in under 1 minute. Pay-as-you-go.
Audio to Text

RECOMMENDATIONS
Use API to fetch this episode